(Q44558742)

4 December 2017

Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). (English)

1 reference

4 December 2017

ventricular dysfunction

1 reference

left ventricular dysfunction

inferred from title

1 reference

1

1 reference

PubMed ID

12932606

4 December 2017

Christopher M O'Connor

series ordinal

2

object named as

Christopher M O'Connor

1 reference

PubMed ID

12932606

4 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Journal of the American College of Cardiology

4 December 2017

1 reference

4 December 2017

42

1 reference

4 December 2017

4

1 reference

4 December 2017

709-711

1 reference

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Diuretic resistance predicts mortality in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Aldosterone in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

The benefit of implementing a heart failure disease management program

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2803%2900766-6

7 January 2021

10.1016/S0735-1097(03)00766-6

Identifiers

DOI

1 reference

4 December 2017

1 reference

PubMed ID

12932606